

PECEIVED

DEC 0 2 2003

TECH CENTER 1500/2900



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Mastrodonato and Braguti

Confirmation No.: 8421

Serial No.: 10/080,736

Art Unit: 1623

Filed: February 22, 2002

Examiner: Michael C. Henry

For:

COMPOSITIONS AND METHODS FOR

Attorney Docket No: 11109-004

THE TREATMENT OR PREVENTION OF

**INFLAMMATION** 

#### INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & § 1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent and Trademark Office of all references coming to the attention of Applicants or Attorneys for Applicants which are or may be related to patentability of the claimed invention, Applicants hereby direct the Examiner's attention to references A01-A05, B01 and C01-C76 which are listed on the accompanying revised PTO Form 1449 entitled "List of References Cited by Applicant." A copy of each of References A01-A05, B01 and C01-C76 is submitted herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants respectfully request that the Examiner consider the foregoing references and that the references be made of record in the file of the above-captioned application.

Pursuant to 37 C.F.R. § 1.97, a fee of \$180.00 is believed to be due. Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes

Respectfully submitted,

Date: November 20, 2003

Hancis D. Cerrito

38,100

Francis D. Cernto

(Reg. No.)

By: William J. Themann

(Reg. No.)

PENNIE & EDMONDS LLP

1155 Avenue of the Americas New York, New York 10036-2711

(212) 790-9090



# RECEIVED

DEC 0 2 2003

### Express Mail No. <u>EV 335 858 512 US</u>

TECH CENTER 1600/2900

ATTY DOCKET NO.

11109-004-999

APPLICATION NO
10/080,736

APPLICANT

Mastrodonato et al.

FILING DATE

GROUP

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

February 22, 2002 1614

#### **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	6,140,312	10/31/00	Falk et al.			
	A02	6,136,793	10/24/00	Falk et al.			• •
	A03	6,114,314	9/5/00	Falk et al.			
	A04	4,736,024	4/5/98	Della Valle et al.			
	A05	4,707,354	11/17/87	Garlen et al.			

			FOREIG	N PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
Г							YES	NO
	↓B01	EP 0 444 492 B1	2/18/91	EPO			X	

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
C01	Abatangelo et al., 1983, "Healing of hyaluronic acid-enriched wounds: histological observations," J. Surg. Res.35(5):410-6
C02	Abatangelo, et al. 1997, "Hyaluronic acid delays or impedes reepithelialization?" J. Burn Care Rehabil. 18(6):552
C03	Akao, et al., 1992, "Inhibitory Effects of Glycyrrhetic Acid and Its Related Compounds on 3□-Hydroxysteroid Dehydrogenase of Rat Liver Cytosol," Chem. Pharm. Bull. (Tokyo), 40(5):1208-1210
C04	Allen, L.V. Jr., Contemporary compounding: Products for stomatitis, U.S. Pharmacist 1990;8, pp. 88-90.
C05	Bao, et al., 1997, "Effect of sodium glycyrrhetinate on chemical peritonitis in rats," Chung Kuo Yao Li Hsueh Pao, 18(3): 277-280
Ç06	Barker, 1999, "Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation," Support Care Cancer 7(1):17-20
,C07	Breast Cancer: Changing Diet and Fitness Questions and Answers downloaded from http://my.webmd.com
C08	Burgess, et al., 1990, "Pharmacological management of recurrent oral mucosal ulceration," Drugs 39(1):54-65
Ç09	Cantelli-Forti, et al., 1997, "Toxicological assessment of liquorice: biliary excretion in rats," Pharmacol. Res. 35(5):463-70
, C10	Carrington Oral Wound Rinse for Oral Mucosa http://www.carringtonlabs.com
Ć11	Carrington Laboratories/Caraloe Product Ingredients, Radiacare Oral Wound Rinse.
,C12	Commentary, 1991, "Oral complications of cancer therapies: diagnosis, prevention, and treatment," The National Institutes of Health Consensus Development Conference Statement, Oncology (Huntingt). 5(7):64, 69-76, 79 passim.
C13	Diary from a Week in Practice dated Dec. 1, 2001 downloaded from www.aafp.org

Sheet 2 of 4

# TECH CENTER 16.

<u></u>	4
C14 PRAC	Don't et al., 1996, "Comparison of methods to determine the prevalence and nature of oral mucositis," Eancer Pract. 4(6):312-8
C15	Dodd, 2001, "A comparison of the affective state and quality of life of chemotherapy patients who do and do not develop chemotherapy-induced oral mucositis," J. Pain Symptom Manage. 21(6):498-505
C16	Dodds, et al., 1997, "Cortisol metabolism and its inhibition by glycyrrhetinic acid in the isolated
	perfused human placental lobule," J. Steroid Biochem. Mol. Biol. 62(4):337-43
E17	Eilers et al., 1988, "Development, testing, and application of the oral assessment guide," Oncol. Nurs. Forum. 15(3):325-30
√C18	Fain Gel: For Vaginal Mucosa http://www.elder-group.com/faingel.html
C19	Ferrari et al., 2001, "In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice," Hypertension 38(6):1330-6
£20	Fujisawa, et al., 2000, "Glycyrrhizin inhibits the lytic pathway of complementpossible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis," Microbiol. Immunol. 44(9):799-804
921	Fujiwara, et al., 1983, "Hypokalemia and Sodium Retention in Patients with Diabetes and Chronic
	Hepatitis Receiving Insulin and Glycyrrhizin," Endocrinol. Japan 20(2):243-249
C22	Glick, et al., 1992, "Alternative therapies for major aphthous ulcers in AIDS patients," J. Am. Dent. Assoc. 123(7):61-5
C23	Gupta et al., 1994, "Interpolymer Complexation and its Effect on Bioadhesive Strength and
	Dissolution Characteristics of Buccal Drug Delivery Systems," Drug Development and Industrial
1	Pharmacy, 20(3):315-325
C24	Hanson, et al., 1997, "Protection from radiation-induced oral mucositis by a mouth rinse containing
	the prostaglandin E1 analog, misoprostol: a placebo-controlled, double-blind clinical trial," Advances
	in Experimental Medicine & Biology 400B:811-818
C25	Heilmann, et al., 1999, "Administration of glycyrrhetinic acid: significant correlation between serum
1 4	levels and the cortisol/cortisone-ratio in serum and urine," Exp. Clin. Endocrinol. Diabetes
	107(6):370-8
. C26	Hodgkin's Disease: Chemo downloaded from www.prism.gatech.edu
, C27	Inoue, et al., 1996, "Inhibitory effect of glycyrrhetinic acid derivatives on capsaicin-induced ear edema in mice," Jpn. J. Pharmacol. 71(4):281-9
£28	Jones, et al., 1998, "Viscoelastic properties of bioadhesive, chlorhexidine-containing semi-solids for
	topical application to the oropharynx," Pharm. Res. 15(7):1131-6
C29	Jones, 1997, "Textural analysis and flow rheometry of novel, bioadhesive antimicrobial oral gels,"
<b></b>	Pharm. Res. 14(4):450-7
C30	Jones, 1996, "Development and mechanical characterization of bioadhesive semi-solid, polymeric
	systems containing tetracycline for the treatment of periodontal diseases," Pharm. Res. 13(11):1734-8
C31	Karthaus, et al., 1999, "Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis
Ψ	- are there new strategies?" Bone Marrow Transplant. 24(10):1095-108
C32	Khaksa, et al., 1996, "Anti-inflammatory and anti-nociceptive activity of disodium glycyrrhetinic acid
	hemiphthalate," Planta Med. 62(4):326-8
C33	Larson et al., 1998, "The PRO-SELF Mouth Aware program: an effective approach for reducing
	chemotherapy-induced mucositis," Cancer Nurs. 21(4):263-8
C34	LeVeque et al., 1992, "Clinical Evaluation of MG209, an Anesthetic, Film-Forming Agent for Relief from Painful Oral Ulcers Associated with Chemotherapy," J. Clin. Onc. 10(12):1964-1968
/C25	Magic Mouthwash downloaded from www.fpnotebook.com
√C35	I
C36	"Magic Mouthwash Recipes" updated November 11, 1999.* Downloaded from what-
	me/hepc/magicmw.html.
C37	Mauricio et al., 1997, "Identification of glycyrrhizin as a thrombin inhibitor," Biochem. Biophys. Res.
1020	Commun. 235(1):259-63  McCarthy et al. 1998 "Pick factors associated with muscasitis in capacity nations receiving 5
C38	McCarthy et al., 1998, "Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil," Oral Oncol. 34(6):484-90
,C39	McGuire et al., 1993, "Patterns of mucositis and pain in patients receiving preparative chemotherapy
Y <sup>239</sup>	and bone marrow transplantation," Oncol. Nurs. Forum. 20(10):1493-502
£40	"Mouth Sores" dated January 12, 1997 downloaded from deltronix.com.

		. = 01. 02.112
	Ç41	Mueller, et al., 1995, "Mucositis management practices for hospitalized patients: national survey results," J. Pain Symptom Manage. 10(7):510-20
DIPE IS	<b>E</b> 42	Mueller, et al., 1995, "Pharmaceutical aspects of mucositis mouthwash mixtures," Am. J. Health Syst Pharm. 52(22):2596-7
2 0 2000	Ç43	Nagao, 1995, "A case of oral lichen planus with chronic hepatitis C successfully treated by glycyrrhizin," Kansenshogaku Zasshi 69(8):940-4
COEMABIL CO.	C44 .	North Carolina Board of Pharmacy, Frequently Asked Questions for Pharmacists downloaded from www.ncbop.org
The state of the s	Ć45	OraMagic: For Oral Mucosa http://www.fda.gov/cdrh/pdf2/k024180.pdf
., /	Ç46	Paoletti, J. and McCord, K., Compounding Mouthwashes and Rinses for Oral Ulcerations, International Journal of Pharmaceutical Compounding, January/February 1999.
\	C47	Pico, et al., 1998, "Mucositis: Its Occurrence Consequences, and Treatment in the Oncology Setting," Oncologist 3(6):446-451
	C48	Plasdone® Povidone USP Technical Profile, International Special Typroducts.
J	C49	Plevova et al., 1999, "Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: a review," Oral Oncol. 35(5):453-70
1	<b>250</b>	Ploeger, et al., 2001, "The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling," Drug Metab. Rev. 33(2):125-47
1	Ć51	ProstaPotek: For Rectal Mucosa http://www.chronicprostatitis.com/algonot.html
1	€52	Quilitz, 1995, "Modulation of Chemotherapy-Induced Mucositis," Cancer Control 2(5):452-459
	253	Randomized clinical trial to treat oral mucositis in patients receiving chemotherapy, dated 1998.  Downloaded from www.ons.org
,5	Ç54	Ryu et al., 1999, "Increased bioavailability of propranolol in rats by retaining thermally gelling liquid suppositories in the rectum," J Control Release. 59(2):163-72
(	C55	Sanzgiri, et al., 1994, "Evaluation of mucoadhesive properties of hyaluronic acid benzyl esters," International Journal of Pharmaceutics (Netherlands), 107: 91-97
, ,	C56	Saxen et al., 1997, "Sustained relief of oral aphthous ulcer pain from topical diclofenac in hyaluronar a randomized, double-blind clinical trial," Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 84(4):356-61
1	C57	Serra, et al., 2002, "Glycyrrhetinic acid decreases plasma potassium concentrations in patients with anuria," J. Am. Soc. Nephrol. 13(1):191-6
, (	C58	Shibata, 2000, "A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice Yakugaku Zasshi. 120(10):849-62
-0	C59	Shintani, et al., 1992, "Glycyrrhizin (Licorice)-Induced Hypokalemic Myopathy," Eur. Neurol. 32:44
,	C60	Sigurjonsdottir, 2001, "Liquorice-induced rise in blood pressure: a linear dose-response relationship, J. Hum. Hypertens. 15(8):549-52
¥	261	Solomonidou, et al., 2001, "Effect of carbomer concentration and degree of neutralization on the mucoadhesive properties of polymer films," J. Biomater. Sci. Polym. Ed. 12(11):1191-205
,0	C62	Stiff, P., 2001, "Mucositis associated with stem cell transplantation: current status and innovative approaches to management," Bone Marrow Transplant. 27 Suppl 2:S3-S11
,(	C63	Tips for Giving Medicine That is Hard to Give (Copyright dates from 1997-2000)
, 0	E64	Van Rossum, et al., 2001, "'Pseudo-aldosteronism' induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients," Journal of Gastroenterology and Hepatology 16(7):789-795
1	C65	Walgreens Kaopectate Children's Anti-diarrheal Liquid Cherry flavor Product Description dowloade from www.walgreens.com.
1	C66	Walgreens Kaopectate Concentrated Anti-Diarrheal Peppermint Flavor Product Description dowloaded from www.walgreens.com.
	C67	Walgreens Kaopectate Concentrated Anti-diarrheal regular flavor Product Description dowloaded from www.walgreens.com.
10	C68	Walgreens Maalox Antacid Product Description dowloaded from www.walgreens.com.

		£ 4762 0 2 6
	C69	Walker, et al., 1995, "Endogenous inhibitors of 11 beta-hydroxysteroid dehydrogenase in Wight Population," J. Clin. Endocrinol. Metab. 80(2):529-33
OIPA	£70	Walker, et al., 1994, "Licorice-induced hypertension and syndromes of apparent mineralocorticol excess," Endocrinol. Metab. Clin. North Am. 23(2):359-77
	e71	Wang, et al., 2001, "Licorice and cancer," Nutr. Cancer. 39(1):1-11
NOV 2 0 2003	C72	Wilkes, 1998, "Prevention and treatment of oral mucositis following cancer chemotherapy," Semin. Oncol. 25(5):538-51
×	C73	Wojtaszek, C., 2000, "Management of chemotherapy-induced stomatitis," Clin. J. Oncol. Nurs. 4(6):263-70
ADEMARA	C74	Woo, et al., 1996, "Recurrent aphthous ulcers: a review of diagnosis and treatment," J. Am. Dent. Assoc. 127(8):1202-13
	C75	Yamamura, et al., 1995, "The Relationship Between Pharmacokinetic Behaviour of Glycyrrhizin and Hepatic Function in Patients with Acute Hepatitis and Liver Cirrhosis," Biopharmaceutics and Drug Disposition 15:13-21
	C76	Yamamura, et al., 1992, "Pharmacokinetic profile of glycyrrhizin in healthy volunteers by a new high-performance liquid chromatographic method," J. Pharm. Sci. 81(10):1042-6

#### **EXAMINER**

## DATE CONSIDERED

\*EX-AMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.